Table 5 |
||||||||
|
Subgroup analysis: identification and management of abnormal CRFs |
||||||||
|
Group A (RA) Rh |
Group A (RA) PCP |
Group B (DM) |
Group C (GP) |
P, Group A (Rh versus PCP) |
P, all three (PCP) |
P, A versus C (PCP) |
||
|
|
||||||||
|
Smoking |
Abnl (n) |
36 |
36 |
48 |
56 |
|||
|
ID |
6 (17%) |
29 (81%) |
40 (83%) |
49 (88%) |
< 0.0001 |
0.7 |
0.4 |
|
|
MA |
5 (14%) |
20 (56%) |
25 (52%) |
34 (61%) |
0.0004 |
0.7 |
0.7 |
|
|
|
||||||||
|
Weight |
Abnl (n) |
160 |
160 |
222 |
162 |
|||
|
ID |
41 (26%) |
72 (45%) |
176 (79%) |
92 (57%) |
0.0004 |
< 0.0001 |
0.04 |
|
|
MA |
13 (8%) |
49 (31%) |
151 (68%) |
74 (46%) |
< 0.0001 |
< 0.0001 |
0.006 |
|
|
|
||||||||
|
SBP |
Abnl (n) |
132 |
132 |
199 |
150 |
|||
|
ID |
119 (90%) |
131 (99%) |
198 (99.9%) |
149 (99%) |
0.001 |
0.9 |
1 |
|
|
MA |
12 (9%) |
44 (33%) |
146 (73%) |
64 (43%) |
< 0.0001 |
< 0.0001 |
0.1 |
|
|
|
||||||||
|
DBP |
Abnl (n) |
45 |
45 |
45 |
52 |
|||
|
ID |
43 (96%) |
45 |
45 |
52 |
0.5 |
1 |
1 |
|
|
MA |
8 (18%) |
18 (40%) |
35 (78%) |
30 (58%) |
0.04 |
< 0.001 |
0.1 |
|
|
|
||||||||
|
HDL |
Abnl (n) |
26 |
26 |
75 |
33 |
|||
|
ID |
2 (8%) |
11 (42%) |
56 (75%) |
22 (67%) |
0.009 |
< 0.01 |
0.07 |
|
|
MA |
1 (4%) |
4 (15%) |
38 (51%) |
13 (39%) |
0.3 |
< 0.0001 |
0.08 |
|
|
|
||||||||
|
LDL |
Abnl (n) |
39 |
39 |
102 |
33 |
|||
|
ID |
1 (3%) |
23 (59%) |
85 (83%) |
26 (79%) |
< 0.0001 |
0.009 |
0.08 |
|
|
MA |
1 (3%) |
16 (41%) |
76 (75%) |
21 (64%) |
< 0.0001 |
0.0009 |
0.06 |
|
|
|
||||||||
|
TG |
Abnl (n) |
53 |
53 |
130 |
54 |
|||
|
ID |
6 (11%) |
31 (59%) |
110 (85%) |
36 (67%) |
< 0.0001 |
< 0.0003 |
0.4 |
|
|
MA |
3 (6%) |
17 (32%) |
86 (66%) |
20 (37%) |
0.0009 |
< 0.0001 |
0.7 |
|
|
|
||||||||
|
FBG |
Abnl (n) |
26 |
26 |
141 |
36 |
|||
|
ID |
0 |
12 (46%) |
135 (96%) |
16 (44%) |
< 0.0001 |
< 0.0001 |
1 |
|
|
MA |
0 |
2 (8%) |
132 (94%) |
8 (22%) |
0.5 |
< 0.0001 |
0.2 |
|
|
|
||||||||
|
All patients included in this subgroup analysis had an abnormal value for a given risk factor. Percentages are calculated as the number of patients with an identified or managed risk factor divided by the number of patients with abnormal values for the given risk factor. Abnl, abnormal; DBP, diastolic blood pressure; DM, diabetes mellitus; FBG, fasting blood glucose; GP, general population; HDL, high-density lipoprotein; ID, identified; LDL, low-density lipoprotein; MA, managed; RA, rheumatoid arthritis; Rh, rheumatologist; SBP, systolic blood pressure; TG, triglyceride. |
||||||||
|
Desai et al. Arthritis Research & Therapy 2012 14:R270 doi:10.1186/ar4118 |
||||||||
